Prothena Competitors

Prothena (NASDAQ:PRTA) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Insider and Institutional Ownership

90.2% of Prothena shares are owned by institutional investors. Comparatively, 81.2% of Apellis Pharmaceuticals shares are owned by institutional investors. 30.4% of Prothena shares are owned by company insiders. Comparatively, 9.5% of Apellis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Prothena and Apellis Pharmaceuticals, as provided by MarketBeat.com.

Prothena currently has a consensus target price of $29.4286, indicating a potential upside of 30.85%. Apellis Pharmaceuticals has a consensus target price of $125.00, indicating a potential upside of 173.76%. Given Apellis Pharmaceuticals' higher possible upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Prothena.

Profitability

This table compares Prothena and Apellis Pharmaceuticals' net margins, return on equity and return on assets.

Volatility & Risk

Prothena has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.

Earnings and Valuation

This table compares Prothena and Apellis Pharmaceuticals' top-line revenue, earnings per share and valuation.

Prothena has higher revenue and earnings than Apellis Pharmaceuticals. Prothena is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Prothena beats Apellis Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Prothena (NASDAQ:PRTA) and Atea Pharmaceuticals (NASDAQ:AVIR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Profitability

This table compares Prothena and Atea Pharmaceuticals' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Prothena and Atea Pharmaceuticals' top-line revenue, earnings per share and valuation.

Atea Pharmaceuticals has lower revenue, but higher earnings than Prothena.

Insider and Institutional Ownership

90.2% of Prothena shares are owned by institutional investors. 30.4% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Prothena and Atea Pharmaceuticals, as provided by MarketBeat.com.

Prothena currently has a consensus target price of $29.4286, indicating a potential upside of 30.85%. Atea Pharmaceuticals has a consensus target price of $69.3333, indicating a potential upside of 65.04%. Given Atea Pharmaceuticals' higher possible upside, analysts plainly believe Atea Pharmaceuticals is more favorable than Prothena.

Prothena (NASDAQ:PRTA) and Emergent BioSolutions (NYSE:EBS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.

Insider & Institutional Ownership

90.2% of Prothena shares are held by institutional investors. Comparatively, 80.2% of Emergent BioSolutions shares are held by institutional investors. 30.4% of Prothena shares are held by company insiders. Comparatively, 14.1% of Emergent BioSolutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for Prothena and Emergent BioSolutions, as provided by MarketBeat.

Prothena currently has a consensus target price of $29.4286, indicating a potential upside of 30.85%. Emergent BioSolutions has a consensus target price of $113.6667, indicating a potential upside of 73.25%. Given Emergent BioSolutions' higher possible upside, analysts clearly believe Emergent BioSolutions is more favorable than Prothena.

Profitability

This table compares Prothena and Emergent BioSolutions' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Prothena and Emergent BioSolutions' top-line revenue, earnings per share (EPS) and valuation.

Emergent BioSolutions has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Prothena has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.

Summary

Emergent BioSolutions beats Prothena on 8 of the 14 factors compared between the two stocks.

Turning Point Therapeutics (NASDAQ:TPTX) and Prothena (NASDAQ:PRTA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.

Valuation & Earnings

This table compares Turning Point Therapeutics and Prothena's gross revenue, earnings per share (EPS) and valuation.

Turning Point Therapeutics has higher earnings, but lower revenue than Prothena. Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Turning Point Therapeutics and Prothena's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Turning Point Therapeutics and Prothena, as provided by MarketBeat.com.

Turning Point Therapeutics currently has a consensus target price of $153.7143, suggesting a potential upside of 117.85%. Prothena has a consensus target price of $29.4286, suggesting a potential upside of 30.85%. Given Turning Point Therapeutics' higher possible upside, equities research analysts clearly believe Turning Point Therapeutics is more favorable than Prothena.

Insider and Institutional Ownership

81.3% of Turning Point Therapeutics shares are held by institutional investors. Comparatively, 90.2% of Prothena shares are held by institutional investors. 23.2% of Turning Point Therapeutics shares are held by company insiders. Comparatively, 30.4% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Turning Point Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Prothena has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.

Summary

Prothena beats Turning Point Therapeutics on 6 of the 11 factors compared between the two stocks.

Prothena (NASDAQ:PRTA) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Insider & Institutional Ownership

90.2% of Prothena shares are owned by institutional investors. Comparatively, 18.9% of Legend Biotech shares are owned by institutional investors. 30.4% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Prothena and Legend Biotech's revenue, earnings per share and valuation.

Prothena has higher earnings, but lower revenue than Legend Biotech.

Profitability

This table compares Prothena and Legend Biotech's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Prothena and Legend Biotech, as reported by MarketBeat.com.

Prothena presently has a consensus price target of $29.4286, suggesting a potential upside of 30.85%. Legend Biotech has a consensus price target of $49.00, suggesting a potential upside of 87.67%. Given Legend Biotech's higher possible upside, analysts clearly believe Legend Biotech is more favorable than Prothena.

Summary

Prothena beats Legend Biotech on 7 of the 10 factors compared between the two stocks.

Prothena (NASDAQ:PRTA) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Volatility and Risk

Prothena has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500.

Insider and Institutional Ownership

90.2% of Prothena shares are owned by institutional investors. Comparatively, 95.3% of Nektar Therapeutics shares are owned by institutional investors. 30.4% of Prothena shares are owned by company insiders. Comparatively, 3.0% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Prothena and Nektar Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for Prothena and Nektar Therapeutics, as reported by MarketBeat.

Prothena currently has a consensus price target of $29.4286, suggesting a potential upside of 30.85%. Nektar Therapeutics has a consensus price target of $25.2857, suggesting a potential upside of 35.22%. Given Nektar Therapeutics' higher possible upside, analysts clearly believe Nektar Therapeutics is more favorable than Prothena.

Earnings and Valuation

This table compares Prothena and Nektar Therapeutics' revenue, earnings per share and valuation.

Prothena has higher earnings, but lower revenue than Nektar Therapeutics. Prothena is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Nektar Therapeutics beats Prothena on 8 of the 14 factors compared between the two stocks.